pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE
Spyre Therapeutics
Spyre Therapeutics clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Waltham, USA HQ
2023 Founded
110 Employees
Public company Type
SYRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2023
- Employees
- 110
- Programs
- 8
- Drugs
- 1
- Patents
- 0
Spyre Therapeutics projects
0 ClinicalTrials.gov programs sponsored by Spyre Therapeutics.
Spyre Therapeutics has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
No programs matched
Frequently asked questions
How many clinical projects does Spyre Therapeutics have?
0 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.